bortezomib + lenalidomide + dexamethasone

This is a combination drug regimen consisting of three agents used primarily for the treatment of multiple myeloma, especially newly diagnosed multiple myeloma (NDMM). - **Bortezomib** is a proteasome inhibitor that blocks proteasomes in cells, leading to accumulation of proteins and subsequent cell death. - **Lenalidomide** is an immunomodulatory agent that modulates the immune system and has anti-angiogenic and anti-cancer effects. - **Dexamethasone** is a corticosteroid that enhances the efficacy of bortezomib and lenalidomide by inducing apoptosis in myeloma cells. The combination (often abbreviated as VRd or RVD) is considered standard-of-care first-line therapy for patients with active multiple myeloma regardless of transplant eligibility. It achieves deep, durable responses with manageable toxicity profiles. The regimen has been studied extensively in clinical trials and real-world settings[1][2][6][8].

Brand names

Revlimid + Velcade + dexamethasone

Other names

Velcade + Revlimid + Dexamethasone